STOCK TITAN

Palatin Technologies, Inc. to Report First Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on November 17, 2020

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

CRANBURY, N.J., Nov. 12, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 before the open of the U.S. financial markets.

Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 17, 2020 at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development.

Schedule for the Operating Results Press Release, Conference Call / Audio Webcast

Q1 Fiscal Year 2021 Results Press Release                         

11/17/2020 at 7:30 a.m. ET



Q1 Fiscal Year 2021 Conference Call-Live                           

11/17/2020 at 11:00 a.m. ET

US/Canada Dial-In Number:                                                 

1-800-353-6461

International Dial-In Number:                                               

1-334-323-0501

Conference ID:                                                                    

3383273



Q1 Fiscal Year 2021 Conference Call-Replay                   

11/17/2020-11/24/2020

US/Canada Dial-In Number:                                             

1-888-203-1112

International Dial-In Number:                                           

1-719-457-0820

Replay Passcode:                                                           

3383273



Audio Webcast Live and Replay Access                       

http://www.palatin.com

The audio webcast and replay can be accessed by logging on to the "Investors-Webcasts" section of Palatin's website at http://www.palatin.com.

About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information, please visit http://www.palatin.com.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/palatin-technologies-inc-to-report-first-quarter-fiscal-year-2021-results-teleconference-and-webcast-to-be-held-on-november-17-2020-301171701.html

SOURCE Palatin Technologies, Inc.

Palatin Technologies, Inc.

NYSE:PTN

PTN Rankings

PTN Latest News

PTN Stock Data

32.27M
15.54M
3.35%
10.72%
9.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CRANBURY

About PTN

palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy